HCW Biologics, Inc. (HCWB)

HCW Biologics Inc. stock has experienced significant volatility, with a substantial decline to $0.47 as of April 30, 2026. In March 2026, the stock price saw a jump due to regaining compliance with Nasdaq listing rules and completing a financing round. The company reported a loss for 2025 and has received "going concern" warnings, indicating doubts about its ability to continue operating. HCW Biologics also reported impairment charges for the fourth quarter ended December 31, 2025, amounting to $1,500,000.

Information regarding the demand seasonality for HCW Biologics Inc.'s products and services is not explicitly available. Stock price seasonality analysis indicates that February has the highest probability of positive returns, while May may not be an ideal month for investment.

HCW Biologics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies for diseases driven by chronic inflammation, particularly age-related conditions. The company utilizes its TOBI and TRBC platforms to create biologics targeting specific immune pathways. Its product candidates include HCW9201, HCW9218, HCW9302, HCW11-018b, HCW11-040, HCW9206, HCW11-006, HCW11-002, HCW11-0027 and HCW11-018. HCW Biologics also has license agreements with Wugen Inc. and WY Biotech Co., Ltd.

HCW Biologics Inc. is headquartered in Miramar, Florida, United States. While its primary focus is within the United States, the company aims to establish global partnerships and secure regulatory approvals in major markets like Europe and Asia.

HCW Biologics' brand reputation has been influenced by both positive and negative events. Positive developments include presenting preclinical data for HCW11-018b and showcasing data for its second-generation T-cell engager IND-enabling study, as well as regaining compliance with Nasdaq listing rules. Negative impacts stem from "going concern" warnings and reported net losses for 2025, raising concerns about financial stability.

HCW Biologics Inc. has 15 institutional owners and shareholders holding a total of 424,435 shares, representing 2.96% of the stock. Major institutional shareholders include Armistice Capital, Llc, DRW Securities, LLC, Citadel Advisors Llc, Susquehanna International Group, Llp, Vanguard Group Inc, Geode Capital Management, Llc, Golden State Wealth Management, LLC, Tower Research Capital LLC (TRC), UBS Group AG, Wells Fargo & Company/mn, J.w. Cole Advisors, Inc. and Advisor Group Holdings. As of December 2025, DRW Holdings held 35,000 shares, Susquehanna International held 20,000 shares, Vanguard Group held 15,000 shares, and Geode Capital Management held 14,000 shares.